Unexploited potential of risk factor treatment in patients with atherosclerotic cardiovascular disease

被引:13
|
作者
van Trier, Tinka J. [1 ]
Snaterse, Marjolein [1 ]
Hageman, Steven H. J. [2 ]
ter Hoeve, Nienke [3 ,4 ]
Sunamura, Madoka [3 ,5 ]
Moll van Charante, Eric P. [6 ]
Galenkamp, Henrike [7 ]
Deckers, Jaap W. [8 ]
Martens, Fabrice M. A. C. [9 ]
Visseren, Frank L. J. [2 ]
Scholte Op Reimer, Wilma J. M. [1 ,10 ]
Peters, Ron J. G. [1 ]
Jorstad, Harald T. [1 ]
机构
[1] Univ Amsterdam, Amsterdam Univ Med Ctr, Dept Cardiol, Amsterdam Cardiovasc Sci, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands
[2] Univ Med Ctr Utrecht, Dept Vasc Med, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands
[3] Capri Cardiac Rehabil Rotterdam, Max Euwelaan 55, NL-3062 MA Rotterdam, Netherlands
[4] Erasmus MC, Dept Rehabil Med, Dr Molewaterplein 40, NL-3015 GD Rotterdam, Netherlands
[5] St Franciscus Gasthuis, Dept Cardiol, Kleiweg 500, NL-3045 PM Rotterdam, Netherlands
[6] Amsterdam Univ Med Ctr, Dept Gen Practice, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands
[7] Amsterdam Univ Med Ctr, Amsterdam Publ Hlth Res Inst, Dept Publ & Occupat Hlth, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands
[8] Erasmus MC, Dept Cardiol, Thoraxctr, Dr Molewaterplein 40, NL-3015 GD Rotterdam, Netherlands
[9] Deventer Hosp, Dept Cardiol, N Bolkesteinlaan 75, NL-7416 SE Deventer, Netherlands
[10] HU Univ Appl Sci Utrecht, Res Grp Chron Dis, Padualaan 99, NL-3584 CH Utrecht, Netherlands
关键词
Risk stratification; Lifetime risk; Cardiovascular risk factors; Secondary prevention; Residual risk; MYOCARDIAL-INFARCTION; WAIST CIRCUMFERENCE; EUROPEAN GUIDELINES; PREVENTION PROGRAM; CLINICAL-PRACTICE; LIFE-STYLE; CARDIOLOGY; COUNTRIES; THERAPY; SOCIETY;
D O I
10.1093/eurjpc/zwad038
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Most patients with atherosclerotic cardiovascular disease remain at (very) high risk for recurrent events due to suboptimal risk factor control. Aims This study aimed to quantify the potential of maximal risk factor treatment on 10-year and lifetime risk of recurrent atherosclerotic cardiovascular events in patients 1 year after a coronary event. Methods and results Pooled data from six studies are as follows: RESPONSE 1, RESPONSE 2, OPTICARE, EUROASPIRE IV, EUROASPIRE V, and HELIUS. Patients aged >= 45 years at >= 6 months after coronary event were included. The SMART-REACH score was used to estimate 10-year and lifetime risk of recurrent atherosclerotic cardiovascular events with current treatment and potential risk reduction and gains in event-free years with maximal treatment (lifestyle and pharmacological). In 3230 atherosclerotic cardiovascular disease patients (24% women), at median interquartile range (IQR) 1.1 years (1.0-1.8) after index event, 10-year risk was median (IQR) 20% (15-27%) and lifetime risk 54% (47-63%). Whereas 70% used conventional medication, 82% had >= 1 drug-modifiable risk factor not on target. Furthermore, 91% had >= 1 lifestyle-related risk factor not on target. Maximizing therapy was associated with a potential reduction of median (IQR) 10-year risk to 6% (4-8%) and of lifetime risk to 20% (15-27%) and a median (IQR) gain of 7.3 (5.4-10.4) atherosclerotic cardiovascular disease event-free years. Conclusions Amongst patients with atherosclerotic cardiovascular disease, maximizing current, guideline-based preventive therapy has the potential to mitigate a large part of their risk of recurrent events and to add a clinically important number of event-free years to their lifetime. Lay Summary Patients with heart disease are at high risk of new cardiac events. This study amongst 3230 patients who had a heart attack or received a stent or bypass surgery shows missed potential for healthy life after a heart attack. The average age of study patients was 61 years, and 24% were women. At 1 year after the cardiac event, nearly one in three (30%) continued smoking, 79% were overweight, 45% reported insufficient physical activity, 40% had high blood pressure, and 65% had a too high LDL ('bad') cholesterol. We calculated that adherence to lifestyle advice and medications could on average halve the risk for another heart attack and add over 7 healthy years of life after a heart attack. This highlights the importance of healthy lifestyle and medication adherence after a heart attack. Key finding:center dot adherence to lifestyle advice and medications could add over 7 healthy years of life after a heart attack
引用
收藏
页码:601 / 610
页数:10
相关论文
共 50 条
  • [11] Cardiovascular Risk Factor Control and Treatment Across the Spectrum of Patients with Atherosclerotic Cardiovascular Disease: The Precision Medicine Initiative - All of Us Study
    Gong, Yufan
    Wong, Nathan D.
    CIRCULATION, 2021, 144
  • [12] A New Treatable Risk Factor for Stroke and Atherosclerotic Cardiovascular Disease?
    Feske, Steven K.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (02) : 159 - 161
  • [14] Periodontal Disease as a Potential Risk Factor of Cardiovascular Disease
    Yamanaka, Futoshi
    Tsujita, Kenichi
    Saito, Shigeru
    CIRCULATION JOURNAL, 2022, 86 (05) : 819 - 820
  • [15] Lifetime risk for atherosclerotic cardiovascular disease by risk factor levels at age 50
    Lloyd-Jones, DM
    Leip, EP
    Larson, MG
    D'Agostino, RB
    Beiser, A
    Wilson, PW
    Wolf, PA
    Levy, D
    CIRCULATION, 2003, 108 (17) : 779 - 780
  • [16] The Impact of Anxiety and Depression Symptoms on Cardiovascular Risk Factor Control in Patients Without a History of Atherosclerotic Cardiovascular Disease
    Pietrzykowski, Lukasz
    Kosobucka-Ozdoba, Agata
    Michalski, Piotr
    Kasprzak, Michal
    Ratajczak, Jakub
    Rzepka-Cholasinska, Alicja
    Siodmiak, Joanna
    Grzelakowska, Klaudyna
    Kubica, Aldona
    VASCULAR HEALTH AND RISK MANAGEMENT, 2024, 20 : 301 - 311
  • [17] Nonalcoholic Fatty Liver Disease as an Emerging Risk Factor and Potential Intervention Target for Atherosclerotic Cardiovascular Diseases
    Zhang, Daqing
    Mi, Zhen
    Peng, Jiya
    Yang, Tiangui
    Han, Yuze
    Zhai, Yujia
    Song, Chenliang
    Teng, Xianzhuo
    Sun, Wei
    Guo, Jing
    Bilonda, Kabeya Paulin
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2023, 81 (05) : 327 - 335
  • [18] Potential value of targeting von Willebrand factor in atherosclerotic cardiovascular disease
    Montoro-Garcia, Silvia
    Shantsila, Eduard
    Lip, Gregory Y. H.
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2014, 18 (01) : 43 - 53
  • [19] Risk of Atherosclerotic Cardiovascular Disease in Patients With Bipolar Disorder and Accuracy of a Cardiovascular Risk Calculator
    Foroughi, Moein
    Medina-Inojosa, Jose R.
    Lopez-Jimenez, Francisco
    Saeidifard, Farzane
    Viniciguerra, Manlio
    Frye, Mark A.
    Morgan, Robert J.
    BIOLOGICAL PSYCHIATRY, 2018, 83 (09) : S283 - S283
  • [20] PROSPECTIVE-STUDY OF LIPOPROTEIN(A) AS A RISK FACTOR FOR ATHEROSCLEROTIC CARDIOVASCULAR-DISEASE IN PATIENTS WITH DIABETES
    HIRAGA, T
    KOBAYASHI, T
    OKUBO, M
    NAKANISHI, K
    SUGIMOTO, T
    OHASHI, Y
    MURASE, T
    DIABETES CARE, 1995, 18 (02) : 241 - 244